FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2920923079> ?p ?o ?g. }

• W2920923079 abstract "LXR-623 (WAY-252623), a liver X receptor agonist, reduces atherosclerotic plaque progression and remarkably inhibits the proliferation of glioblastoma cells, owing to its brain-penetrant ability. However, the role of LXR-623 against the proliferation of other cancer cells and the underlying mechanism remain unknown. Long non-coding RNAs (lncRNAs) serve as novel and crucial regulators that participate in cancer tumorigenesis and diverse biological processes. Here, we report a previously uncharacterized mechanism underlying lncRNA-mediated exocytosis of LXR-623 via the phosphatase and tensin homolog (PTEN)/protein kinase B (AKT)/p53 axis to suppress the proliferation of cancer cells in vitro. We found that LXR-623 significantly inhibited the proliferation and induced apoptosis and cell cycle arrest at S phase in breast cancer cells in a concentration- and time-dependent manner. Experiments using a xenograft mouse model revealed the inhibitory effects of LXR-623 on tumor growth. We used lncRNA microarray to investigate the potential genes regulated by LXR-623. As a result, LINC01125 was found to be significantly upregulated in the cells treated with LXR-623. Gain- and loss-of-function assays were conducted to investigate the anti-proliferation role of LINC01125. LINC01125 knockdown resulted in the inhibition of the cytotoxic effect of LXR-623; in contrast, LINC01125 overexpression significantly enhanced the effect of LXR-623. LXR-623 and LINC01125-mediated anti-growth regulation is, at least in part, associated with the participation of the PTEN/AKT/mouse double minute 2 homolog (MDM2)/p53 pathway. In addition, SF1670, a specific PTEN inhibitor with prolonged intracellular retention, may strongly block the anti-proliferation effect induced by LXR-623 and LINC01125 overexpression. Chromatin immunoprecipitation (ChIP) assay results suggest that p53 binds to the promoter of LINC01125 to strengthen the expression of the PTEN/AKT pathway. Taken together, our findings suggest that LXR-623 possesses significant antitumor activity in breast cancer cells that is partly mediated through the upregulation in LINC01125 expression and enhancement in apoptosis via the PTEN/AKT/MDM2/p53 pathway." @default.
• W2920923079 created "2019-03-22" @default.
• W2920923079 creator A5000033521 @default.
• W2920923079 creator A5026906414 @default.
• W2920923079 creator A5027792113 @default.
• W2920923079 creator A5056557589 @default.
• W2920923079 creator A5057613380 @default.
• W2920923079 creator A5089505260 @default.
• W2920923079 date "2019-03-01" @default.
• W2920923079 modified "2023-10-15" @default.
• W2920923079 title "The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway" @default.
• W2920923079 cites W1569244981 @default.
• W2920923079 cites W1850984254 @default.
• W2920923079 cites W1963933860 @default.
• W2920923079 cites W1983057459 @default.
• W2920923079 cites W2040524925 @default.
• W2920923079 cites W2046178435 @default.
• W2920923079 cites W2062465243 @default.
• W2920923079 cites W2082377269 @default.
• W2920923079 cites W2127714324 @default.
• W2920923079 cites W2146573461 @default.
• W2920923079 cites W2147254800 @default.
• W2920923079 cites W2152488169 @default.
• W2920923079 cites W2212385672 @default.
• W2920923079 cites W2279483485 @default.
• W2920923079 cites W2334785451 @default.
• W2920923079 cites W2348844796 @default.
• W2920923079 cites W2368378997 @default.
• W2920923079 cites W2463219782 @default.
• W2920923079 cites W2520895538 @default.
• W2920923079 cites W2530768869 @default.
• W2920923079 cites W2559956261 @default.
• W2920923079 cites W2563331414 @default.
• W2920923079 cites W2768583786 @default.
• W2920923079 cites W2769072373 @default.
• W2920923079 cites W2788783025 @default.
• W2920923079 cites W2795174081 @default.
• W2920923079 cites W2807431507 @default.
• W2920923079 cites W2807500538 @default.
• W2920923079 cites W2883496207 @default.
• W2920923079 cites W2885730177 @default.
• W2920923079 cites W2885758487 @default.
• W2920923079 cites W2886600771 @default.
• W2920923079 doi "https://doi.org/10.1038/s41419-019-1440-5" @default.
• W2920923079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6416354" @default.
• W2920923079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30867411" @default.
• W2920923079 hasPublicationYear "2019" @default.
• W2920923079 type Work @default.
• W2920923079 sameAs 2920923079 @default.
• W2920923079 citedByCount "26" @default.
• W2920923079 countsByYear W29209230792019 @default.
• W2920923079 countsByYear W29209230792020 @default.
• W2920923079 countsByYear W29209230792021 @default.
• W2920923079 countsByYear W29209230792022 @default.
• W2920923079 countsByYear W29209230792023 @default.
• W2920923079 crossrefType "journal-article" @default.
• W2920923079 hasAuthorship W2920923079A5000033521 @default.
• W2920923079 hasAuthorship W2920923079A5026906414 @default.
• W2920923079 hasAuthorship W2920923079A5027792113 @default.
• W2920923079 hasAuthorship W2920923079A5056557589 @default.
• W2920923079 hasAuthorship W2920923079A5057613380 @default.
• W2920923079 hasAuthorship W2920923079A5089505260 @default.
• W2920923079 hasBestOaLocation W29209230791 @default.
• W2920923079 hasConcept C104317684 @default.
• W2920923079 hasConcept C121608353 @default.
• W2920923079 hasConcept C2777609662 @default.
• W2920923079 hasConcept C502942594 @default.
• W2920923079 hasConcept C530470458 @default.
• W2920923079 hasConcept C54355233 @default.
• W2920923079 hasConcept C62112901 @default.
• W2920923079 hasConcept C62203573 @default.
• W2920923079 hasConcept C62478195 @default.
• W2920923079 hasConcept C67705224 @default.
• W2920923079 hasConcept C75217442 @default.
• W2920923079 hasConcept C86554907 @default.
• W2920923079 hasConcept C86803240 @default.
• W2920923079 hasConcept C95444343 @default.
• W2920923079 hasConceptScore W2920923079C104317684 @default.
• W2920923079 hasConceptScore W2920923079C121608353 @default.
• W2920923079 hasConceptScore W2920923079C2777609662 @default.
• W2920923079 hasConceptScore W2920923079C502942594 @default.
• W2920923079 hasConceptScore W2920923079C530470458 @default.
• W2920923079 hasConceptScore W2920923079C54355233 @default.
• W2920923079 hasConceptScore W2920923079C62112901 @default.
• W2920923079 hasConceptScore W2920923079C62203573 @default.
• W2920923079 hasConceptScore W2920923079C62478195 @default.
• W2920923079 hasConceptScore W2920923079C67705224 @default.
• W2920923079 hasConceptScore W2920923079C75217442 @default.
• W2920923079 hasConceptScore W2920923079C86554907 @default.
• W2920923079 hasConceptScore W2920923079C86803240 @default.
• W2920923079 hasConceptScore W2920923079C95444343 @default.
• W2920923079 hasIssue "3" @default.
• W2920923079 hasLocation W29209230791 @default.
• W2920923079 hasLocation W29209230792 @default.
• W2920923079 hasLocation W29209230793 @default.
• W2920923079 hasOpenAccess W2920923079 @default.
• W2920923079 hasPrimaryLocation W29209230791 @default.
• W2920923079 hasRelatedWork W1993312761 @default.
• W2920923079 hasRelatedWork W2219191688 @default.
• W2920923079 hasRelatedWork W2511723070 @default.

• next